Molecular Oncology
Volume 3, Issue 5 , Pages 469-482, December 2009

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models

  • Anna Bergamaschi

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
  • ,
  • Geir Olav Hjortland

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
  • ,
  • Tiziana Triulzi

      Affiliations

    • Department of Experimental Oncology, National Cancer Institute, Milan, Italy
  • ,
  • Therese Sørlie

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Department of Informatics, University of Oslo, Norway
  • ,
  • Hilde Johnsen

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
  • ,
  • Anne Hansen Ree

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Akershus University Hospital, Lorenskog, Norway
  • ,
  • Hege Giercksky Russnes

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
  • ,
  • Sigurd Tronnes

      Affiliations

    • Akershus University Hospital, Lorenskog, Norway
  • ,
  • Gunhild M. Mælandsmo

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
  • ,
  • Oystein Fodstad

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Faculty Division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Norway
  • ,
  • Anne-Lise Borresen-Dale

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Faculty Division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Norway
  • ,
  • Olav Engebraaten

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Faculty Division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Norway
    • Corresponding Author InformationCorresponding author at: Department of Tumor Biology, Norwegian Radium Hospital, Ullernchausseen 70, Montebello, N-0310 Oslo, Norway.

Received 22 May 2009; received in revised form 18 July 2009; accepted 21 July 2009. published online 06 August 2009.

Abstract 

The number of relevant and well-characterized cell lines and xenograft models for studying human breast cancer are few, and may represent a limitation for this field of research. With the aim of developing new breast cancer model systems for in vivo studies of hormone dependent and independent tumor growth, progression and invasion, and for in vivo experimental therapy studies, we collected primary mammary tumor specimens from patients, and implanted them in immunodeficient mice. Primary tumor tissue from 29 patients with breast cancer was implanted subcutaneously with matrigel in SCID mice, in the presence of continuous release of estradiol. The tumors were transferred into new animals when reaching a diameter of 15mm and engrafted tumors were harvested for morphological and molecular characterization from passage six. Further, gene expression profiling was performed using Agilent Human Whole Genome Oligo Microarrays, as well as DNA copy number analysis using Agilent Human Genome CGH 244K Microarrays. Of the 30 primary tumors implanted into mice (including two implants from the same patient), two gave rise to viable tumors beyond passage ten. One showed high expression levels of estrogen receptor-α protein (ER) while the other was negative. Histopathological evaluation of xenograft tumors was carried out at passage 10–12; both xenografts maintained the morphological characteristics of the original tumors (classified as invasive grade III ductal carcinomas). The genomic profile of the ER-positive xenograft tumor resembled the profile of the primary tumor, while the profile obtained from the ER-negative parental tumor was different from the xenograft. However, the ER-negative parental tumor and xenograft clustered on the same branch using unsupervised hierarchical clustering analysis on RNA microarray expression data of “intrinsic genes”. A significant variation was observed in the expression of extracellular matrix (ECM)-related genes, which were found downregulated in the engrafted tumors compared to the primary tumor. By IHC and qRT-PCR we found that the downregulation of stroma-related genes was compensated by the overexpression of such molecules by the mouse host tissue. The two established breast cancer xenograft models showed different histopathological characteristics and profound diversity in gene expression patterns that in part can be associated to their ER status and here described as basal-like and luminal-like phenotype, respectively. These two new breast cancer xenografts represent useful preclinical tools for developing and testing of new therapies and improving our knowledge on breast cancer biology.

Keywords: Breast cancer, Model system, Luminal, Basal, RNA microarray, Genome array

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(09)00102-1

doi:10.1016/j.molonc.2009.07.003

Molecular Oncology
Volume 3, Issue 5 , Pages 469-482, December 2009